[1]
|
Konstantinopoulos, P.A., Liu, J.F., Barry, W.T., Krasner, C.N., Buss, M.K., Birrer, M.J., et al. (2017) Phase 2, Two-Group, Two-Stage, Open-Label Study of Avelumab in Patients with Microsatellite Stable, Microsatellite Instable and POLE-Mutated Recurrent or Persistent Endometrial Cancer. Journal of Clinical Oncology, 35, Article ID: TPS5615.
https://doi.org/10.1200/JCO.2017.35.15_suppl.TPS5615
|
[2]
|
Morice, P., Leary, A., Creutzberg, C., Abu-Rustum, N. and Darai, E. (2016) Endometrial Cancer. The Lancet Journal, 387, 1094-1108. https://doi.org/10.1016/S0140-6736(15)00130-0
|
[3]
|
Arthur, R.S., Kabat, G.C., Kim, M.Y., et al. (2019) Meta-bolic Syndrome and Risk of Endometrial Cancer in Postmenopausal Women: A Prospective Study. Cancer Causes Con-trol, 30, 355-363.
https://doi.org/10.1007/s10552-019-01139-5
|
[4]
|
Friberg, E., Orsini, .N, Mantzoros, C.S. and Wolk, A. (2007) Diabetes Mellitus and Risk of Endometrial Cancer: A Meta-Analysis. Diabetologia, 50, 1365-1374. https://doi.org/10.1007/s00125-007-0681-5
|
[5]
|
Bokhman, J.V. (1983) Two Pathogenetic Types of Endometrial Carcinoma. Gynecologic Oncology, 15, 10-17.
https://doi.org/10.1016/0090-8258(83)90111-7
|
[6]
|
Musacchio, L., Boccia, S.M., Caruso, G., et al. (2020) Im-mune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients? Journal of Clinical Medicine, 9, Arti-cle No. 1721. https://doi.org/10.3390/jcm9061721
|
[7]
|
Wilczyński, M., Danielska, J. and Wilczyński, J. (2016) An Update of the Classical Bokhman’s Dualistic Model of Endometrial Cancer. Przegląd Menopauzalny, 15, 63-68. https://doi.org/10.5114/pm.2016.61186
|
[8]
|
Liu, Y.L. and Zamarin, D. (2018) Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers. Current Oncology Reports, 20, Article No. 94.
https://doi.org/10.1007/s11912-018-0740-8
|
[9]
|
Brooks, R.A., Fleming, G.F., Lastra, R.R., et al. (2019) Current Recommendations and Recent Progress in Endometrial Cancer. CA: A Cancer Journal for Clinicians, 69, 258-279. https://doi.org/10.3322/caac.21561
|
[10]
|
周琦, 吴小华, 刘继红, 李力, 朱笕青, 白萍, 盛修贵. 子宫内膜癌诊断与治疗指南(第四版) [J]. 中国实用妇科与产科杂志, 2018, 34(8): 880-886.
|
[11]
|
Green, A.K., Feinberg, J. and Makker, V. (2020) A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer. American Society of Clinical Oncology Educational Book, 40, 238-244.
https://doi.org/10.1200/EDBK_280503
|
[12]
|
Smyth, M.J., Ngiow, S.F., Ribas, A. and Teng, M.W. (2016) Combi-nation Cancer Immunotherapies Tailored to the Tumour Microenvironment. Nature Reviews Clinical Oncology, 13, 143-158.
https://doi.org/10.1038/nrclinonc.2015.209
|
[13]
|
Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of Cancer: The Next Generation. Cell, 144, 646-674.
https://doi.org/10.1016/j.cell.2011.02.013
|
[14]
|
Longoria, T.C. and Eskander, R.N. (2015) Immunotherapy in En-dometrial Cancer—An Evolving Therapeutic Paradigm. Gynecologic Oncology Research and Practice, 2, Article No. 11. https://doi.org/10.1186/s40661-015-0020-3
|
[15]
|
Keir, M.E., Butte, M.J., Freeman, G.J. and Sharpe, A.H. (2008) PD-1 and Its Ligands in Tolerance and Immunity. Annual Review of Immunology, 26, 677-704. https://doi.org/10.1146/annurev.immunol.26.021607.090331
|
[16]
|
Wu, Y., Chen, W., Xu, Z.P. and Gu, W. (2019) PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition. Frontiers in Im-munology, 10, Article 2022.
https://doi.org/10.3389/fimmu.2019.02022
|
[17]
|
Freeman, G.J., Long, A.J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., et al. (2000) Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation. Journal of Experimental Medicine, 192, 1027-1034. https://doi.org/10.1084/jem.192.7.1027
|
[18]
|
Selby, M.J., et al. (2013) Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells. Cancer Immunology Research, 1, 32-42.
https://doi.org/10.1158/2326-6066.CIR-13-0013
|
[19]
|
Pardoll, D.M. (2012) The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nature Reviews Cancer, 12, 252-264. https://doi.org/10.1038/nrc3239
|
[20]
|
Parsa, A.T., et al. (2007) Loss of Tumour Suppressor PTEN Function Increases B7‑H1 Expression and Immunoresistance in Glioma. Nature Medicine, 13, 84-88. https://doi.org/10.1038/nm1517
|
[21]
|
Hamanishi, J., Mandai, M., Iwasaki, M., et al. (2007) Programmed Cell Death 1 Ligand 1 and Tumor-Infiltrating CD8+ T Lymphocytes Are Prognostic Factors of Hu-man Ovarian Cancer. Proceedings of the National Academy of Sciences of the United States of America, 104, 3360-3365. https://doi.org/10.1073/pnas.0611533104
|
[22]
|
Okazaki, T. and Honjo, T. (2007) PD-1 and PD-1 Ligands: From Discovery to Clinical Application. International Immunology, 19, 813-824. https://doi.org/10.1093/intimm/dxm057
|
[23]
|
许标波, 贺毅憬, 王韦力, 等. 肿瘤免疫检查点抑制剂临床治疗的研究进展[J]. 中国临床药理学与治疗学, 2016, 21(2): 218-224.
|
[24]
|
Herzog, T.J., Arguello, D., Reddy, S.K. and Gatalica, Z. (2015) PD-1, PDL1 Expression in 1599 Gynecological Cancers: Implications for Immunotherapy. Gyneco-logic Oncology, 137, 204-205.
https://doi.org/10.1016/j.ygyno.2015.01.514
|
[25]
|
Marabelle, A., Le, D.T., Ascierto, P.A., Di Giacomo, A.M., De Jesus-Acosta, A., Delord, J.-P., Geva, R., Gottfried, M., Penel, N., Hansen, A.R., et al. (2020) Efficacy of Pembroli-zumab in Patients with Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results from the Phase II KEYNOTE-158 Study. Journal of Clinical Oncology, 38, 1-10. https://doi.org/10.1200/JCO.19.02105
|
[26]
|
Fleming, G.F., Emens, L.A., Eder, J.P., Hamilton, E.P., Liu, J.F., Liu, B., Molinero, L., Fasso, M., O’Hear, C. and Braiteh, F.S. (2017) Clinical Activity, Safety and Biomarker Results from a Phase Ia Study of Atezolizumab (Atezo) in Advanced/Recurrent Endometrial Cancer (rEC). Journal of Clinical Oncology, 35, Article No. 5585.
https://doi.org/10.1200/JCO.2017.35.15_suppl.5585
|
[27]
|
McDermott, D.F., Sosman, J.A., Sznol, M., Massard, C., Gordon, M.S., Hamid, O., et al. (2016) Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates from a Phase Ia Study. Journal of Clinical Oncology, 34, 833-842.
https://doi.org/10.1200/JCO.2015.63.7421
|
[28]
|
Zitvogel, L., Galluzzi, L., Smyth, M.J. and Kroemer, G. (2013) Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance. Immunity, 39, 74-88.
https://doi.org/10.1016/j.immuni.2013.06.014
|
[29]
|
Colombo, N., Preti, E., Landoni, F., Carinelli, S., Colombo, A., Marini, C. and Sessa, C. (2013) Endometrial Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Annals of Oncology, 24, vi33-vi38.
https://doi.org/10.1093/annonc/mdt353
|
[30]
|
McMeekin, S., Dizon, D., Barter, J., Scambia, G., Manzyuk, L., Lis-yanskaya, A., Oaknin, A., Ringuette, S., Mukhopadhyay, P., Rosenberg, J., et al. (2015) Phase III Randomized Trial of Second-Line Ixabepilone versus Paclitaxel or Doxorubicin in Women with Advanced Endometrial Cancer. Gynecologic Oncology, 138, 18-23.
https://doi.org/10.1016/j.ygyno.2015.04.026
|
[31]
|
Labiano, S., Palazon, A. and Melero, I. (2015) Immune Response Regulation in the Tumor Microenvironment by Hypoxia. Seminars in Oncology, 42, 378-386. https://doi.org/10.1053/j.seminoncol.2015.02.009
|
[32]
|
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D.G. and Jain, R.K. (2018) Enhancing Cancer Immunotherapy Using Antiangiogenics: Opportunities and Challenges. Nature Re-views Clinical Oncology, 15, 325-340.
https://doi.org/10.1038/nrclinonc.2018.29
|
[33]
|
Makker, V., Taylor, M.H., Aghajanian, C., Oaknin, A., Mier, J., Cohn, A.L., Romeo, M., Bratos, R., Brose, M.S., DiSimone, C., et al. (2020) Lenvatinib plus Pembrolizumab in Patients with Advanced Endometrial Cancer. Journal of Clinical Oncology, 38, 2981-2992. https://doi.org/10.1200/JCO.19.02627
|
[34]
|
Demaria, S. and Formenti, S.C. (2012) Radiation as an Immunological Adjuvant: Current Evidence on Dose and Fractionation. Frontiers in Oncology, 2, Article 153. https://doi.org/10.3389/fonc.2012.00153
|
[35]
|
Sharabi, A.B., Lim, M., DeWeese, T.L. and Drake, C.G. (2015) Ra-diation and Checkpoint Blockade Immunotherapy: Radiosensitisation and Potential Mechanisms of Synergy. The Lancet Oncology, 16, e498-e509.
https://doi.org/10.1016/S1470-2045(15)00007-8
|
[36]
|
Hallahan, D., Kuchibhotla, J. and Wyble, C. (1996) Cell Ad-hesion Molecules Mediate Radiation-Induced Leukocyte Adhesion to the Vascular Endothelium. Cancer Research, 56, 5150-5155.
|
[37]
|
Tuyaerts, S., Van Nuffel, A.M.T., Naert, E., Van Dam, P.A., Vuylsteke, P., De Caluwé, A., Aspeslagh, S., Dirix, P., Lippens, L., De Jaeghere, E., et al. (2019) PRIMMO Study Protocol: A Phase II Study Combining PD-1 Blockade, Radiation and Immunomodulation to Tackle Cervical and Uterine Cancer. BMC Cancer, 19, Article No. 506.
https://doi.org/10.1186/s12885-019-5676-3
|
[38]
|
Kato, Y., Tabata, K., Hori, Y., Tachino, S., Okamoto, K. and Matsui, J. (2015) Abstract A92: Effects of Lenvatinib on Tumor-Associated Macrophages Enhance Antitumor Activity of PD-1 Signal Inhibitors. Molecular Cancer Therapeutics, 14, Article No. A92. https://doi.org/10.1158/1535-7163.TARG-15-A92
|
[39]
|
Michot, J.M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) Immune-Related Adverse Events with Immune Checkpoint Blockade: A Comprehensive Review. European Journal of Cancer, 378, 158-168. https://doi.org/10.1016/j.ejca.2015.11.016
|
[40]
|
Kumar, V., Chaudhary, N., Garg, M., Floudas, C.S., Soni, P. and Chandra, A.B. (2017) Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Frontiers in Pharmacology, 8, Article 49. https://doi.org/10.3389/fphar.2017.00049
|
[41]
|
Postow, M. and Wolchok, J. (2016) Toxicities Associated with Checkpoint Inhibitor Immunotherapy. In: Post, T.W., Ed., UpToDate, UpToDate Inc., Waltham.
|
[42]
|
Weber, J.S. (2012) Practical Management of Immune Related Adverse Events from Immune Checkpoint Protein Antibodies for the Oncolo-gist. American Society of Clinical Oncology Educational Book, 32, 174-177.
https://doi.org/10.14694/EdBook_AM.2012.32.79
|
[43]
|
Minor, D., Chin, K. and Kashani-Sabet, M. (2009) Inflixi-mab in the Treatment of Anti-CTLA4 Antibody (Ipilimumab) Induced Immune-Related Colitis. Cancer Biotherapy & Radiopharmaceuticals, 24, 321-325.
https://doi.org/10.1089/cbr.2008.0607
|
[44]
|
Bagchi, S., Yuan, R. and Engleman, E.G. (2021) Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annual Review of Pathology: Mechanisms of Disease, 16, 223-249.
https://doi.org/10.1146/annurev-pathol-042020-042741
|
[45]
|
Saglam, O. and Conejo-Garcia, J. (2018) PD-1/PD-L1 Immune Checkpoint Inhibitors in Advanced Cervical Cancer. Integrative Cancer Science and Therapeutics, 5. https://doi.org/10.15761/ICST.1000272
|
[46]
|
Lao, Y., Shen, D., Zhang, W., He, R. and Jiang, M. (2022) Immune Checkpoint Inhibitors in Cancer Therapy—How to Overcome Drug Resistance? Cancers, 14, Article No. 3575. https://doi.org/10.3390/cancers14153575
|
[47]
|
Ishizuka, J.J., Manguso, R.T., Cheruiyot, C.K., et al. (2019) Loss of ADAR1 in Tumours Overcomes Resistance to Immune Checkpoint Blockade. Nature, 565, 43-48. https://doi.org/10.1038/s41586-018-0768-9
|
[48]
|
Ryan, N.A.J., Glaire, M.A., Blake, D., Cabrera-Dandy, M., Evans, D.G. and Crosbie, E.J. (2019) The Proportion of Endometrial Cancers Associated with Lynch Syndrome: A Systematic Review of the Literature and Meta-Analysis. Genetics in Medicine, 21, 2167-2180. https://doi.org/10.1038/s41436-019-0536-8
|
[49]
|
Crosbie, E.J., Ryan, N.A., Arends, M.J., Bosse, T., Burn, J., Cornes, J.M., Crawford, R., Eccles, D., Frayling, I.M., Ghaem-Maghami, S., et al. (2019) The Manchester International Consensus Group Recommendations for the Management of Gynecological Cancers in Lynch Syndrome. Genetics in Medicine, 21, 2390-2400.
https://doi.org/10.1038/s41436-019-0489-y
|